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ABSTRACT 
 
In order to identify anti-proliferative compounds from selected Latin American plants, 
approximately 200 plant extracts were screened by the MTS assay  (3-[4,5-dimethylthiazol-2yl]-
5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H tetrazolium).  Vassobia breviflora 
(Solanaceae), was identified as the most active of the species tested in this study. Following a 
bioassay-guided approach, withaferin A was isolated and characterized. This withanolide-type 
steroidal lactone  showed anti-proliferative activities with IC50 values from 0.5 to 2.2 µM 
against head and neck squamous cell carcinoma (HNSCC) MDA1986, JMAR, UM-SCC-2 and 
JHU011. A mechanistic study showed that withaferin A induced apoptosis and cell death in 
HNSCC cells as well as a shift from G0/G1 to G2/M arrest in cell cycle studies. Western data 
demonstrated that the anti-proliferative action of withaferin A could be in part explained through 
degradation of total Akt levels as well as decrease in activation of Akt levels. In order to 
establish anticancer structure activity relationships, three analogues were semi-synthesized from 
withaferin A, and ten related withanolides, including a new chlorinated withanolide 6α-chloro-
5β,17α-dihydroxywithaferin, were isolated from Withania somnifera (Solanaceae). All structures 
were elucidated on the basis of spectroscopic methods (IR, MS, and 1D/2D NMR). X-ray 
crystallography confirmed the absolute configuration of the new withanolide. A method for 
large-scale isolation of withaferin A from W. somnifera was also developed and presented.  
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I. INTRODUCTION 
 
The use of medicines from nature has a long history of development and application by humans.  
Plant medicines have been well documented in ancient Egypt, India, China, Greece and Rome. 
One of the earliest Egyptian medicine records, the “Edwin Smith Papyrus”, is dated circa 3000 
BCE.[1] In India, traditional medicine composed of different system such as Ayurveda, Siddha, 
Unani, homeopathy and naturopathy, has been thriving for many centuries.[2] China also has a 
rich heritage of traditional plant medicine, which dates back more than 4,000 years. Due to their 
long historical use and reliable therapeutic efficacy, traditional plant medicines are still widely 
used in these countries.  
 
Medicinal plants are also gaining more attention from contemporary pharmaceutical academic 
institutes, as they are an important source for the discovery and development of new natural 
bioactive compounds, and provide a diversity of lead structures for the development of synthetic 
and/or semi-synthetic analogs. In Newman and Cragg’s review, 63% of the 974 new chemical 
entities introduced from January 1981 to December 2007 were natural products, modified natural 
products or synthetic compounds with a natural product pharmacophore. When considering 
cancer chemotherapies, among 196 anticancer drugs introduced, 79.8% were naturally derived or 
inspired.[3] For example, Paclitaxel, which was first isolated and characterized from the Pacific 
Yew tree Taxus brevifolia in 1971 by Wani and colleagues in North Carolina,[4] is clinically 
used against breast, lung and ovarian cancer. It is the best-selling cancer drug ever manufactured. 
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Camptothecin is another widely used plant derived anticancer agent, which is a cytotoxic 
quinoline alkaloid first isolated and identified from Camptotheca acuminata in 1966 by Wall and 
colleages.[5]  
 
Over 1.7 million of the world’s species of animals, plants and algae have been described in the 
IUCN red list of threatened species, 2010.[6] According to the estimates made by scientists, 5 
million to over 50 million species live on the planet earth.[7] However, among ca. 320,000 plant 
species recorded, only a small portion has been explored. Marine organisms and microorganisms 
are nearly undiscovered. Therefore, finding new drug leads from natural origins is still one of the 
methods followed in drug lead discovery, especially for cancer research. 
 
Medicinal plants usually contain complex constituents, such as fatty acids, polyketides, 
terpenoids, steroids, and alkaloids, so the evaluation, standardization and quantification of the 
active ingredients are usually difficult to determine in whole plant samples. Efficient methods are 
therefore required for the separation and identification of these active ingredients from other 
components in plants. The field of science to study physical, chemical, biochemical and 
biological properties of drugs, drug substances, or potential drugs or drug substances of natural 
origin as well as the search for new drugs from natural sources, is defined as pharmacognosy by 
the American Society of Pharmacognosy. The purpose of this thesis work was to search for anti-
proliferative compounds from selected Latin American plants that have not been previously 
investigated in detail. 
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The classical phytochemical methods for finding bioactive natural products are to isolate the 
compound first, then to screen its particular activities in vitro or in vivo through different types of 
bioassays. Chemical and chromatographic techniques used in isolation and purification processes 
include liquid-liquid phase extraction, thin-layer chromatography (TLC), preparative TLC 
(PTLC), column chromatography, medium pressure liquid chromatography (MPLC), high-
performance liquid chromatography (HPLC) and liquid chromatography-mass spectroscopy (LC-
MS). Spectroscopic methods such as IR, 1D and 2D NMR, and UV are used for identifying the 
isolated compounds. 
 
Isolation and identification of compounds from plants is a time consuming activity while many 
pure compounds isolated may show no activity whatsoever after the biological assays are 
performed. In this research project, a bioassay guided fractionation was applied for searching 
anticancer bioactive compounds. Instead of screening the pure compounds from two genera in 
the family Solanaceae, fractions at each purification stage were screened in order to shorten the 
process of identifying the active molecules. Chapter 2 gives a detailed account of the bioassay 
directed isolation and structure determination process as it was applied to the CH2Cl2-MeOH 
(1:1) extracts of the Argentinean plant Vassobia breviflora. This work ended up with the 
identification of one anticancer active compound, withaferin A. 
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When an active compound was identified, the mechanistic study of its activity was initiated, and 
in order to establish its structure-activity relationships (SAR), following efforts would be focused 
on either synthesizing analogues of this compound or searching for analogues from the same 
plant species or other related plants in the same genus or family. In Chapter 2, the synthesis of 
three analogues of withaferin A and the results of their anti-proliferative studies were described. 
In Chapter 3, 10 other withaferin A-like compounds were isolated from a related member in the 
Solanaceae, Withania somnifera.  
 
Since the anticancer mechanistic study of withaferin A showed prominent results (Chapter 2), to 
continue the pre-clinical study and further clinical study and establish a completely SAR for its 
anticancer activity, a large quantity of withaferin A was required for these purposes. A method 
for large-scale isolation of withaferin A from W. somnifera was developed and presented in 
Chapter 4. The method was developed to isolate gram-scale withaferin A efficiently from a 
kilogram-scale of raw plant materials. 
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II. WITHANOLIDES FROM VASSOBIA BREVIFLORA 
 
2.1 Introduction 
 
Head and neck squamous cell carcinoma (HNSCC) represents the fifth leading cause of cancer in 
humans, with over 780,000 new cases diagnosed yearly worldwide.[8-10] Platinum-based 
therapy remains the most effective treatment option for HNSCC, but due to its  significant 
toxicity, including ototoxicity, peripheral neuropathy, and nephrotoxicity, it may lead to up to 
15% of deaths.[11] New treatment options such as molecular-targeted therapies are being 
explored to improve survival rates. Epidermal growth factor receptor (EGFR) targeting drugs, 
such as Cetuximab, have shown some advantages but limited efficacy.[12] Novel drugs 
discovered for this disease, especially from natural product sources, would provide a promising 
avenue for preclinical exploration in HNSCC.  
 
Our program routinely screens plant extracts for anticancer activity in HNSCC in collaboration 
with Dr. Mark Cohen of the KU Medical Center. A library of extracts from 200 plants from 
Latin America was evaluated for their cytotoxic activities against four human HNSCC cell lines 
(JMAR, MDA 1986, UM-SCC-2 and JHU011 cells) using a MTS (3-[4,5-dimethylthiazol-2yl]-
5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H tetrazolium) viability assay.  Further 
fractionation and bioassay-guided isolation of the most active plant extracts led to the isolation 
and identification of anti-proliferative compounds. Vassobia breviflora (Sendtn.) Hunz 
(Solanaceae) was identified as the most active of the species tested in the study.  
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2.2 Botany and Collection of V. breviflora 
 
Vassobia, a member of the family Solanaceae, is related to Acnistus, Dunalia, and Iochroma, 
which are also genera endemic to South America.[13] Vassobia belongs to the subtribe 
Iochrominae and includes seven species, which are V. atropoides, V. breviflora, V. brevifolia, V. 
dichotoma, V. fasciculata, V. iochromoides and V. lorentzii. The plant V. breviflora, commonly 
known in Argentina as “pucancho” and “uchucho”, is a widespread spiny shrub with small, 
purple, campanulate and glabrous flowers.[14] V. breviflora has been reported to have 
antimicrobial activity.[15] 
 
Aerial parts of V. breviflora were collected as part of an NIH International Cooperative 
Biodiversity Groups Program. The plant biomass was collected by R. Fortunato and A. Cabral 
along Highway RN 86, 2 km north east of Primavera, Department Patino, Province of Formosa, 
Argentina (lat. 25°14'0"S, long. 57°57'0"W) on November 25, 1999.  A voucher specimen (No. 
ARP 612) identified by R. Fortunato was deposited in the Herbarium (BAB) of the Institute of 
Biological Resources, National Institute of Agricultural Technology (INTA), Castelar, Buenos 
Aires, Argentina.  Intellectual Property Rights Agreements for plant collections and 
interdisciplinary research have been executed between the collaborating institutions in the US 
and Argentina. 
 
2.3 Systematics and Phytochemistry of the Solanaceae 
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The large family Solanaceae, the nightshade family, contains 102 genera and nearly 2500 species 
distributed worldwide.[16] Based on biological effects and since ancient times, humans have 
used plants of the Solanaceae for the prevention and treatment of diseases. For instance, 
Mandragora officinarum was valued in ancient Greece and Rome for its intoxicating and 
narcotic properties and was used as a surgical anesthetic.[17] Furthermore, the common 
vegetables potatoes, peppers, eggplants and tomatoes in this family make it economically 
important as the basis of human food. Solanaceae and Convolvulaceae are sister families in the 
order of Solanales sharing similar phylogeny, morphologic-anatomical properties, 
phytogeographic distribution, and secondary metabolism.  
 
The Solanaceae family contributes high-valued natural products used in traditional medicine, 
pharmacology and drug therapy. Alkaloids, phenolics, flavonoids, lignans, sterols, carotenoids, 
capsaicinoids, steroidal saponins, steroidal alkaloids, withanolides, phytosterols and 
petuniasteroids are examples of specific secondary metabolites present in this family. 
 
Withanolides, a significant group of compounds in the Solanaceae, are steroidal lactones built on 
an ergostane skeleton of 28 carbons. The first withanolide, “withaferin A”, was discovered as a 
constituent of the leaves of Withania somnifera, also called Indian Ginseng, by Lavie et al. in 
1965.[18] To date, over 300 withanolides have been isolated, most of them from genera 
belonging to the Solanaceae.[19] Besides Withania, the genera Acnistus, Datura, Deprea, 
Exodeconus, Iochroma, Jaborosa, Physalis, Salpichroa and Vassobia are reported to contain 
withanolide-like compounds. 
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2.4 Bioassay Guided Fractionation 
 
In order to determine the source of the anticancer activity in V. breviflora, a bioactivity guided 
fractionation was employed. This method enabled the isolation of bioactive compounds without 
having to examine every component of an extract or fraction. At each stage of purification, the 
fractions obtained were screened for their anticancer activities in JMAR, MDA 1986, UM-SCC-
2 and JHU011 human HNSCC cells using the MTS assay.  
 
Dried and ground aerial parts of V. breviflora (100 g) were extracted at room temperature with 
CH2Cl2-MeOH (1:1) three times to afford 9.8 g of a brown crude extract. The crude extract 
exhibited activity against MDA1986, JMAR, UM-SCC-2 and JHU011 cancer cell lines using 
MTS test with the half-maximum inhibitory concentration (IC50) values of 1.1, 7.3, 0.94 and 1.1 
µg/mL respectively. The crude extract was dissolved in 500 mL of MeOH-H2O (1:9) and then 
placed in a separatory funnel to which 500 mL of hexane were added in order to remove the non-
polar lipophilic organics such as fatty acids. The hexane layer was subjected to two additional 
liquid-liquid partitions. The hexane layers were combined and concentrated under reduced 
pressure to obtain a total of 0.79 g of a crude hexane extract. The water layers were each further 
placed in the separatory funnel to which 500 mL of EtOAc were added in order to extract 
organic compounds of mid-polarity. The extraction process was repeated twice and the organic 
layers were combined and concentrated under reduced pressure to yield a total of 2.65 g of a 
crude EtOAc extract. Subsequently, the water layers were each extracted with BuOH three times 
(500 mL × 3) to afford a total of 2.63 g of a crude BuOH extract, which contained most of the 
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polar organics. After all the described extraction procedures were completed, the aqueous layers 
were discarded. Among the three extracts, the EtOAc extract showed the highest activity against 
MDA1986, JMAR, UM-SCC-2 and JHU011 cancer cell lines using MTS test with the half-
maximum inhibitory concentration (IC50) values of 1.2, 6.7, 0.87 and 1.2 µg/mL respectively.  In 
order to narrow down the search for the active constituents in the most active sample, we 
concentrated our isolation and characterization studies to the EtOAc extract.  
 
The EtOAc extract was subjected to a silica gel column chromatography (32-60 µm, 5 × 60 cm) 
and eluted with gradient mixtures of CH2Cl2-MeOH (100:0, 98:2, 95:5, 93:7, 90:10, 80:20, 50:50 
and 0:100), in order of increasing polarity. A total of 182 fractions were collected, and after 
pooling similar fractions based on TLC profiles, fractions 49-54 (830.3 mg; CH2Cl2-MeOH 93:7) 
were combined and confirmed by MTS assay as the most active fractions. These fractions were 
further purified by normal-phase SPE (20 g; 60 ml) using a step gradient of CH2Cl2-MeOH 
mixtures (90:10, 85:15, 80:20, 75:25, 70:30, 65:35, 60:40, 50:50, and 0:100). Among the nine 
collected fractions (Table 2.1), fraction 5 (CH2Cl2-MeOH 70:30) was the most active one by 
displaying anti-proliferative activity against MDA1986, JMAR, UM-SCC-2 and JHU011 cancer 
cell lines with IC50 values of 0.9, 1.0, 1.0 and 1.1 µg/ml. When examined by TLC, fraction 5 
showed one major red spot (compound 1) when sprayed with CHCl3-Hexane-EtOAC-MeOH 
(72:40:18:8). After crystallization using 20 mL of CHCl3-MeOH (1:1), 50 mg of compound 1 
were obtained. Additionally, 20 mg of Fraction 3 (CH2Cl2-MeOH 80:20) were obtained and its 
TLC showed the presence of one purple spot (compound 2). 
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Table 2.1.  Fractionation of Fractions 49-54 from EtOAc extract of V. breviflora. 
Fractions Wt. (in mg) %Yielda 
1 21 2.5 
2 86 10.3 
3 20 2.5 
4 32 3.9 
5 78 9.4 
6 121 14.6 
7 148 17.8 
8 21 2.5 
9 145 17.4 
aAs a percentage of Fractions 49-54 (830.3 mg) from EtOAc extract of V. breviflora. 
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2.5 Structure Elucidation and Identification 
 
Compound 1 (Figure 2.1) was isolated as colorless block-shape crystals. Its HRMS showed an 
[M+H]+ ion at m/z 471.2730 corresponding to the molecular formula C28H39O6. The IR spectrum 
suggested the presence of hydroxyl (3421 cm-1) and carbonyl (1678 cm-1) groups. The 13C and 
DEPT spectra indicated the presence of four methyls, seven methylenes (including one 
oxygenated at δ 57.0), ten methines (including two olefins at δ 142.5 and δ 132.3), and seven 
quaternary carbons (Table 2.2). Of the four methyls, three were identified as tertiary methyls 
base on HSQC and 1H spectra. In HMBC spectra, the tertiary methyl protons at δ 0.71 had strong 
correlations with carbon at δ 39.2, δ 42.5, δ 51.8 and δ 56.0; the tertiary methyl protons at δ 1.42 
had strong correlations with carbon at δ 44.0, δ 47.8, δ 63.9 and δ 202.3. Based on HSQC and 
HMBC information, a steroidal skeleton was assigned to compound 1. The tertiary methyl 
protons on the side chain at δ 2.03 were correlated to one methylene carbon at δ 29.8 and two 
olefins at δ 125.6 and δ 153.5 in HMBC, indicating the presence of an unsaturated lactone side 
chain. Therefore, a withanolide structure was identified based on 1D and 2D NMR spectra 
(Figure 2.2). In addition, compound 1 co-chromatography with an authentic withaferin A sample 
purchased from Chromadex (Irvine, CA) confirmed its structural assignment. Furthermore, the 
X-ray structure (Figure 2.3) of compound 1 was also calculated as withaferin A. 
 
Compound 2 (Figure 2.1) was determined to be a close analog of compound 1 from the 1D and 
2D NMR spectra. Instead of an α, β-unsaturated ketone, the double bond on ring A (C-2, δ132.3 
and C-3, δ142.5 in compound 1)  was reduced and an additional hydroxyl group was attached to 
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carbon three in 2(C-2, δ43.9 and C-3, δ69.6 in compound 2). The rest of the structure was 
determined to be the same as in withaferin A based on NMR data (Figure 2.4). Compound 2 was 
identified as viscosalactone B by comparison of its NMR data with those reported in the 
literature.[20] 
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Figure 2.1. Withaferin A (1) and Viscosalactone B (2) from V. breviflora. 
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Table 2.2.  13C NMR data for withaferin A (1) and viscosalactone B (2). 
  
Positions 1a 2b 
1 202.3 213.0 
2 132.3 43.9 
3 142.5 69.6 
4 69.8 78.9 
5 63.9 65.7 
6 61.7 59.9 
7 29.8 31.1 
8 31.1 32.6 
9 44.0 50.0 
10 47.8 51.9 
11 21.8 22.5 
12 39.2 28.3 
13 42.5 44.3 
14 56.0 56.5 
15 24.2 25.6 
16 27.2 28.6 
17 51.8 53.2 
18 11.6 12.1 
19 17.0 15.3 
20 38.7 40.5 
21 13.3 13.8 
22 78.7 80.2 
23 29.8 30.8 
24 153.5 158.0 
25 125.6 126.5 
26 167.0 168.6 
27 57.0 57.4 
28 20.0 20.4 
a 13C NMR data for withaferin A (1) recorded in CDCl3 at 125 MHz. 
b 13C NMR data for viscosalactone B (2) recorded in CD3OD at 125 MHz. 
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Figure 2.2. 1D and 2D NMR spectra of withaferin A (1). 
A. 1H NMR spectrum (500 MHz, CDCl3) of withaferin A (1). 
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Figure 2.2. 1D and 2D NMR spectra of withaferin A (1) – (cont.) 
B. COSY spectrum of withaferin A (1). 
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Figure 2.2. 1D and 2D NMR spectra of withaferin A (1) - (cont.) 
C. HSQC spectrum of withaferin A (1). 
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Figure 2.2. 1D and 2D NMR spectra of withaferin A (1) - (cont.) 
D. HMBC spectrum of withaferin A (1). 
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Figure 2.3. ORTEP view of withaferin A (1) from X-ray diffraction data.  
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Figure 2.4. 1H NMR spectrum (500 MHz, CD3OD) of viscosalactone B (2). 
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2.6 Anti-proliferative Activity 
 
The anticancer activities of all isolates from V. breviflora were determined against a variety of 
cancer cell lines using a MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H tetrazolium] assay. Compound 1 reduced cell viability of HNSCC cell lines and 
inhibited their growth in a concentration dependent manner. The IC50 values in UM-SCC-2, 
MDA1986, JMAR and JHU-011 cells were 0.5, 0.8, 2.0 and 2.2 µM, respectively. The results 
showed that these four cell lines were very sensitive to the treatment with compound 1 while the 
most sensitive one was the UM-SCC-2 cell line. Compound 1 also showed anti-proliferative 
activity against melanoma cell lines B16F10, NPA, DRO and SKMEL28 with the IC50 values 
0.7, 1.3, 1.4 and 3.3 µM, respectively. Compound 2 was less active than compound 1 in our 
assay against HNSCC cell lines, showing no activity with the concentration of 1 µg/mL. 
 
2.7 Anti-proliferative Mechanistic Study  
 
In order to investigate a possible mechanism for the anti-proliferative effect of compound 1, a 
series of experiments to evaluate cell-cycle arrest and the apoptotic pathway were performed. As 
shown in Figure 2.5, treatment of MDA1986, JMAR, UM-SCC-2, and JHU011 HNSCC cells 
with 3.0 µM of compound 1 for 24 h induced a shift of cells from G0/G1 arrest to a significant 
increase in the percentage of cells in the G2/M phase, from 27% to 42% in JMAR cells (Figure 
2.5A) and from 26% to 49% in MDA1986 cells (Figure 2.5B; p <0.01). The G2/M phase shift 
for UM-SCC-2 cells was from 27% to 36% (Figure 2.5C) and for JHU011 cells, 25% to 34% 
(Figure 2.5D, p <0.01). Compound 1 additionally induced S phase arrest in JMAR, UM-SCC-2 
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and JHU011 cells. Treatment with compound 1 also led to an increase in sub-G0 levels in both 
JMAR (from 2% to 12%; p <0.01) and MDA1986 cells (from 7% to 8%; not significant), 
suggesting that JMAR cells underwent DNA fragmentation, one of the early biochemical events 
leading to apoptosis.  
 
In order to confirm the apoptotic action induced by compound 1, cells were treated with 5.0 µM 
of compound 1 for 24 h and stained with annexin V/propidium iodide (PI). As shown in Figure 
2.6, treatment of HNSCC cells with compound 1 increased the annexin V-positive cells. Staining 
only with Annexin V signified the early apoptotic events whereas dual staining with annexin V 
and PI indicated the late phase of apoptosis. Treatment of JHU011 cells with compound 1 
induced early apoptotic events (p <0.01) significantly from basal levels of 4.8% to 14.8%. There 
was a slight increase in the late phase of apoptosis induced by compound 1 in JHU011 cells, with 
very small staining only with PI (necrosis) observed in JHU011 cells treated with compound 1. 
Treatment of JMAR and UM-SCC-2 cells with compound 1 induced significant increases in 
early and late apoptosis as well as necrosis (p <0.01). MDA1986 cells seemed less sensitive to 
treatment with compound 1, since withaferin A did not increase annexin V/PI staining herein.  
 
To confirm the annexin V studies on HNSCC cells, caspase 3 activation was investigated in 
HNSCC (Figure 2.7). Treatment of JHU011 cells induced activation of the caspase 3 enzyme, as 
signified by decreased procaspase 3 levels. In addition, the caspase 3 substrate PARP was 
cleaved upon treatment with 1, in a concentration-dependent manner (Figure 2.7). Treatment 
with compound 1 at 1.0 µM increased PARP cleavage in JHU011 cells. JMAR cells treated with 
compound 1 also showed similar decreases in procaspase 3 levels and cleavage of PARP protein, 
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in a concentration-dependent fashion. Similar results were also observed when UM-SCC-2 cells 
were treated with compound 1. Treatment of MDA1986 cells with withaferin A increased 
caspase 3 activation and PARP cleavage. However, in line with the annexin V/PI data, a slightly 
higher concentration of compound 1 was required to induce caspase 3 activation in MDA1986 
cells (Figure 2.7). These results indicate that compound 1 induced cell-cycle arrest at the G2/M 
phase and apoptosis was confirmed by positive annexin V/PI staining as well as caspase 3 
activation in the HNSCC cell lines investigated. The G2/M cell cycle arrest is a typical marker of 
apoptosis, and defects in the G2/M arrest check point may allow a damaged cell to enter mitosis 
and undergo apoptosis.[21] At this point, it is not clear whether G2/M cell cycle arrest provides 
conditions inducive of caspase 3 activation.  
 
The effect of withaferin A (1) was examined on major prosurvival signaling pathways in 
HNSCC cells including PI3 kinase/Akt and ERK1/2 MAP kinase. These data showed that 
compound 1 reduced phosphorylation (ser473) as well as total Akt levels in all HNSCC cells in a 
concentration-dependent manner (Figure 2.8). Treatment of JHU011, JMAR, and UM-SCC-2 
cells with as low as 100-250 nM concentrations of compound 1 reduced Akt phosphorylation. It 
is interesting to note that a higher concentration of compound 1 was required to inhibit Akt 
activity in MDA1986 cells (2.5 µM). In addition to the effect of compound 1 on the reduction of 
phosphorylated Akt, the total Akt levels were decreased significantly in all cell lines examined 
(Figure 2.8). These data show that compound 1 is a strong Akt inhibitor in HNSCC cells. The 
effect of compound 1 was examined on ERK1/2 activation in HNSCC cells.  Withaferin A 
increased phosphorylation of ERK1/2 MAP kinase in JHU011, JMAR, and MDA1986 cells. 
Only at higher concentrations did compound 1 inhibit activation of ERK1/2 in UMSCC-2 cells. 
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Withaferin A had no effect on total ERK1/2 levels. All the anti-proliferative activity and 
mechanism studies have been done by Dr. Mark Cohen and his group, and the collaborative 
results were published in 2010.[22] 
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Figure 2.5. Detection of S and G2/M cell cycle arrest in withaferin A (1) treated cells by flow 
cytometry. JMAR (A) MDA1986 (B), UM-SCC-2 (C), and JHU011 (D) cells were treated with 
DMSO or 3.0 µM 1. Cells treated with vehicle (DMSO) were primarily at the G0/G1 phase, while 
cells treated with compound 1 showed shifts from the G0/G1 to the S and G2/M phases.  
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Figure 2.6. Withaferin A (1) induced apoptosis in head and neck squamous cell carcinoma 
(HNSCC) cells. HNSCC cells were treated with 5.0 µM of 1 for 24 h and then harvested and 
stained with annexin V and propidium iodide followed by analysis by flow cytometry. All 
experiments were performed in triplicate. Treatment with 1 exhibited an increase in annexin V 
and PI staining that indicated early as well as late apoptotic events. JMAR cells treated with 1 
showed significant necrosis.  
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Figure 2.7. Caspase 3 was activated in head and neck squamous cell carcinoma cells treated with 
withaferin A (1). HNSCC cells were treated with different concentrations of 1 for 24 h. Levels of 
pro-caspase 3 (inactive form) were examined with the antibody against uncleaved caspase 3. In 
addition, activation of caspase 3 was examined with levels of the uncleaved and cleaved caspase 
3 substrate, PARP. Compound 1 induced caspase 3 activation in all HNSCC cell lines in a 
concentration-dependent manner. 
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Figure 2.8. Compound 1 modulated prosurvival signal transduction pathway. HNSCC cells were 
treated with increasing concentrations of 1 for 24 h. Total levels of phospho-Akt, total Akt, 
phospho-ERK and total ERK2 were determined by Western blotting. Antibody against β-actin 
was used as a protein loading control. Compound 1 reduced activation of Akt as well as total 
cellular Akt, while ERK1/2 was activated in JHU011, JMAR, and MDA1986 cells while 
ERK1/2 activity decreased in UM-SCC-2 cells at a high concentration of 1. Total ERK levels 
remained unchanged with compound 1 treatment. 
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2.8 Synthesis of Withaferin A Analogues 
 
In order to investigate a possible SAR for the antiproliferative activity of withaferin A, three 
analogues were semi-synthesized from withaferin A. Compounds 1a and 1b (Figure 2.9) were 
prepared by step hydrogenation of withaferin A.[18] Withaferin A (10 mg) in EtOAc (3.2 mL) 
was hydrogenated over 10% palladium on charcoal (1 mg) at room temperature and atmospheric 
pressure for 3 h. The reaction solution was filtered and washed with 100 ml of MeOH, and then 
concentrated under reduced pressure to obtain a total of 9.5 mg of product. The TLC of the 
reaction product showed two major spots, which were pink (Rf = 0.3, compound 1a) and orange 
(Rf = 0.5, compound 1b) after spraying with vanillin-sulfuric acid reagent. To separate both 
compounds, this product was further purified by semi-prep HPLC eluting with CH3CN-H2O 
(50:50). Compound 1a (1.2 mg) was collected at the retention time of 17 min and compound 1b 
(7.8 mg) was at 28 min. Compound 1b was recrystallized using CHCl3 and EtOAc (2:1) to afford 
light yellow parallelepiped-shaped crystals.  
 
Compound 1c (Figure 2.9) was prepared by acetylation of withaferin A.[23] Withaferin A (5 
mg) was dissolved in dry pyridine (350 µL) and mixed with an excess of acetic anhydride (1 
mL). The reaction mixture was refluxed for 1 h (about 60 ºC) and then poured into ice-cold 
water. A white crystalline precipitate was formed in the mixture, which was then extracted with 
CHCl3 (50 mL) using a separatory funnel. The organic layer was concentrated under reduced 
pressure to afford 4.9 mg of product. This reaction product was further purified by a silica gel 
column (5 g, 12~26 µm, Sorbent Technologies), which was eluted with EtOAc-hexane (1:1), to 
obtain 4.3 mg of compound 1c.  
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By comparison with the reported data,[24] compound 1a was identified as a 2,3-dihydroxy 
derivative of withaferin A (1). The obvious difference between 1 and 1a was that the double bond 
between C-2 (δ 132.3) and C-3 (δ 142.5) in withaferin A was reduced to a single bond C-2 
(δ 31.8) and C-3 (δ 26.5) (Table 2.3) in compound 1a (Figure 2.10). The structure of 1b was 
confirmed by proton NMR (Figure 2.11) and through single-crystal X-ray diffraction 
experiments (Figure 2.13) as 2,3-dihydro-27-deoxywithaferin A. Compound 1c was confirmed 
as diacetylwithaferin A, which displayed two additional pairs of a carbonyl group and a methyl 
group compared to withaferin A on 13C NMR (DEPT) spectra (Figure 2.12 and Table 2.3). 1D 
and 2D NMR spectra and X-ray structure of compound 1 refer to Figure 2.2 described in section 
2.5. 
 
The IC50 values of compound 1c against cancer cell lines MDA1986 and JMAR were 0.95 and 
0.98 µM, which were similar to those obtained for withaferin A. Compound 1c was not active at 
20 µM against cancer cell lines JHU011 and UMSCC2. Compound 1a and 1b did not show any 
activity at 20 µM against all four HNSCC cancer cell lines. 
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Figure 2.9. 2,3-Dihydrowithaferin A (1a), 2,3-dihydro-27-deoxywithaferin A (1b) and 
diacetylwithaferin A (1c) synthesized from withaferin A.  
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 Figure 2.10.  1H NMR spectrum (400 MHz, CDCl3) of 2,3-dihydrowithaferin A (1a).  
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Figure 2.11. 1H NMR spectrum (400 MHz, CDCl3) of 2,3-dihydro-27-deoxywithaferin A (1b). 
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Figure 2.12. 1H NMR spectrum (400 MHz, CDCl3) of diacetylwithaferin A (1c). 
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Figure 2.13. ORTEP view of 2,3-dihydro-27-deoxywithaferin A (1b) from X-ray diffraction 
data. 
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Table 2.3.  13C NMR dataa for 2,3-dihydrowithaferin A (1a), 2,3-dihydro-27-deoxywithaferin A 
(1b) and diacetylwithaferin A (1c). 
  
Positions 1a 1b 1c         
1 210.3 210.3 201.0 
2 31.8 31.8 133.6 
3 26.5 26.2 139.5 
4 72.2 72.2 72.0 
5 65.8 65.7 61.2 
6 58.3 58.3 60.1 
7 29.2 29.2 30.0 
8 31.0 31.0 30.9 
9 42.5 42.5 44.0 
10 50.0 50.0 48.1 
11 21.1 21.2 21.3 
12 27.3 27.2 27.1 
13 42.3 42.3 42.7 
14 55.9 55.6 56.1 
15 23.8 23.8 24.0 
16 38.7 38.6 39.1 
17 51.4 51.3 51.7 
18 11.3 11.2 11.4 
19 15.0 15.1 15.1 
20 38.1 38.1 38.1 
21 13.3 13.3 13.3 
22 78.2 78.0 77.9 
23 28.9 28.8 28.9 
24 152.0 150.1 157.2 
25 125.2 122.0 121.9 
26 167.0 168.6 165.2 
27 57.5 12.6 57.9 
28 20.0 20.5 20.5 
C4-C=O - - 170.0 
C4-CO-CH3 - - 20.8 
C27-C=O - - 170.4 
C27-CO-CH3 - - 20.8 
a 13C NMR data were recorded in CDCl3 at 125 MHz.
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2.9 Experimental 
 
General Experimental Procedures 
NMR spectra were recorded on either a Bruker DRX-400 with a qnp probe or on a Bruder AV-
500 with a cryoprobe. 1H and 13C spectra of compound 1 were recorded using the residual 
protonated signal in the CDCl3 solvent (δH 7.24) or the central peak of the CDCl3 triplet (δC 
77.00) as the internal standard. Chemical shifts of compound 2 were expressed in ppm (d) using 
the residual protonated signal in the CD3OD solvent at δ 3.31 (1H) and δ 49 (13C) as reference. 
Normal phase TLC was performed on Sorbent Technologies Silica G TLC plates (200 µm, 
w/UV 254) using the solvent system DCM-EtOAc-MeOH (1:8:1), and reverse phase TLC was 
performed on Sorbent Technologies C18 TLC plates (150 µm, w/UV 254) using H2O-MeOH 
(1:1). Spots were visualized using UV light (254 nm) and spraying with vanillin-sulfuric acid 
reagent. 
 
Bioassay Materials 
Culture media, fetal bovine serum (FBS), penicillin G, streptomycin, MEM-nonessential amino 
acids, ribonuclease A, and propidium iodide (PI) were purchased from Sigma-Aldrich (St. Louis, 
MO). MEM-vitamin solution was purchased from Life Technologies, Inc. (Grand Island, NY). 
MTS reagents were purchased from Promega Co (Madison, WI). Annexin V was from BD 
Bioscience (Bedford, MA). Primary antibodies against total ERK and β-actin and secondary 
antibodies against mouse and rabbit antibodies were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA). Primary antibodies against phospho-Akt, total-Akt, phospho-ERK, caspase 3 
and PARP were obtained from Cell Signaling Technologies (Beverly, MA). BCA protein assay 
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reagents were purchased from Pierce (Rockford, IL). Protease inhibitor mixture set II was 
purchased from Calbiochem (San Diego, CA). 
 
Cell Culture and Media 
The invasive oral squamous carcinoma cell lines, JMAR and MDA1986, were a gift to Dr. Mark 
Cohen from Dr. Jeffrey Myers (University of Texas, M.D. Anderson Cancer Center; Houston, 
TX). The head and neck squamous carcinoma cell line, UM-SCC-2, was a gift from Dr. Scott 
Weed (University of West Virginia, Morgantown, WV). The cells were grown in DMEM 
supplemented with 10% FBS, sodium pyruvate, nonessential amino acids, L-glutamine, a two-
fold MEM-vitamin solution, and 1% penicillin/streptomycin. The laryngeal squamous carcinoma 
cell line, JHU-011, was kindly donated by Dr. Joseph Califano (Johns Hopkins University, 
Baltimore, MD). This was cultured in RPMI-1640, supplemented with 10% FBS and 1% 
penicillin/streptomycin. Adherent monolayer cultures were maintained on plastic plates and 
incubated at 37 °C with 5% CO2. 
 
Cytotoxicity Assay 
The experiment was performed by a MTS assay according to the manufacturer’s instructions. In 
brief, 1 was dissolved in dimethylsulfoxide (DMSO) and then diluted with culture media to 
prepare serial concentrations while the controls received only DMSO (<0.1%, v/v). The cells 
were seeded in 96-well microtiter plates (2×103 cells/well) in 100 µL of growth medium. After 
incubation for 24 h, varying levels of plant extracts or 1 were added to each well, and incubated 
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for 72h. Then, 20 µL MTS solution were added. After 3 h of incubation at 37 oC (5% CO2), 
absorbance was measured at 490 nm with a microplate reader. Percentage viability was 
calculated as a fraction of the negative control (culture medium only), with data plotted as a 
function of % cell viability vs. concentration of 1. The half-maximal inhibitory concentration 
(IC50) was obtained from the MTS viability curves using GraphPad Prisim 5. All studies were 
performed in triplicate. In parallel with wells of the test samples, negative control wells with 
predetermined cell numbers were used to normalize the absorbance readings and to provide 
internal confirmation that the assay was linear over the range of absorbance and cell numbers 
measured. 
 
Western Blot Analysis 
After treatment cells were lysed (0.5% Nonidet P-40, 100 mM, 10 mM Tris (pH 7.5), 1:500 
protease inhibitor mixture set II, 1 mM NaF, and 1 mM sodium orthovanadate) they were placed 
on ice for 20 min. Clear lysates were obtained by centrifugation (14,000 × g for 20 min). Equal 
amounts of protein were separated by SDS-PAGE and electro-transferred onto a Hybond 
nitrocellulose membrane (Amersham). The membranes were blocked and probed with the 
appropriate dilution of primary antibody overnight at 4 oC. The blots were washed three times in 
PBS-Tween-20 for 10 min, and then incubated in horseradish peroxidase-conjugated secondary 
antibody in PBS-Tween-20 at room temperature for 1 h. After washing in PBS-Tween-20, the 
proteins were visualized by enhanced chemiluminescence reagent (Amersham) and captured on 
Kodak XAR-5 film (Eastman Kodak, Rochester, NY). Where indicated, the blots were re-probed 
with antibody against β-actin to ensure equal loading and transfer of proteins. 
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Cell Cycle Arrest Study 
After treatment, cells were trypsinized and 1×106 cells washed with 0.9% NaCl and fixed with 
70% cold ethanol for 30 min at room temperature. After centrifugation (700 ×g; 5 minutes) cells 
were stained with propidium iodide (50 µg/mL in PBS) for 30 min. Then, cells were treated with 
DNAse free RNAse (1 mg/mL) for 30 min and analyzed by a Becton Dickinson LSRII Flow 
Cytometer. 
 
Apoptosis Analysis 
In order to evaluate the induction of apoptosis cells were co-stained with annexin V-propidium 
iodide (PI) and analyzed with flow cytometry. An analysis of phosphatidylserine on the outer 
leaflet of apoptotic cell membranes was performed using annexin V-FITC and PI to distinguish 
between apoptotic and necrotic cells. After treatment, cells (1×106 cells/ml) stained with 
annexin-V and PI according to manufacturer’s instruction (BD Pharmingen, San Diego, CA). To 
each tube, 400 µL of 1x annexin binding buffer was added and stained cells were analyzed using 
a flow cytometer (BD LSRII; Becton Dickerson, San Diego, CA). 
 
Statistical Methods 
Statistical analysis was carried out using student t-test and Fisher’s exact test. Means were 
calculated from three independent experiments. 
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III.WITHANOLIDES ISOLATED FROM WITHANIA SOMNIFERA 
 
3.1 Introduction 
 
In order to establish withaferin A anticancer structure activity relationships, additional amounts 
of withaferin A and a series of its analogues were highly desired. As the original source of plant 
material Vassobia breviflora from Argentina was no longer available for isolation of withaferin 
A, we searched for an alternative source of this compound. After conducting a thorough 
literature search, we chose Withania somnifera Dunal (Solanaceae) as our commercial source of 
the desired material.  Because withaferin A was one of the major compounds in W. somnifera, 
and more than 70 other withanolides from this plant have been reported in the literature,[25] This 
species was the best target for our purpose. Recently, more unusual withanolides were isolated 
and identified from aeroponically grown W. somnifera, including compounds with sulfate,[26] 
uracil and adeninyl[27]. 
 
Withania somnifera, commonly known as “Ashwagandha” and widely cultivated in the drier 
parts of India, is well known and has a long history of use in Ayurvedic medicine.  This “Indian 
Ginseng” has medical use nearly in all disorders that affect human health. In addition, it is used 
as general body tonic and expected to promote mental health, rejuvenate the body in debilitated 
condition and increase longevity.[28] Withaferin A and other withanolides from this plant are 
also reported to be responsible for its anticancer activities. [29] 
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Withanolides are a group of naturally occurring C28-steroidal lactones built on an intact or 
rearranged ergostane scaffold in which C-22 and C-26 are appropriately oxidized for forming a 
δ-lactone ring on the nine-carbon side chain. These compounds are mainly found in members of 
the plant family Solanaceae and named after Withania somnifera from which the first 
withanolide, withaferin A, was isolated. Beside anticancer, withanolides are known to possess 
various other biological benefits including anticarcinogenic,[30] antioxidant,[31] 
adaptogenic,[32] antiparkinsonism,[33] antibacterial,[34] anti-inflammatory,[35] 
immunomodulatory[36] and antidepressant[37] effects.  
 
From this plant, we isolated withaferin A and 10 related withanolides also shown in Figure 3.1. 
compounds isolated included 6α-chloro-5β,17α-dihydroxywithaferin A (3), (22R)-5β-formyl-
6β,27-dihydroxy-1-oxo-4-norwith-24-enolide (4), 2,3-dihydrowithaferin A (5), 3-methoxy-2,3-
dihydrowithaferin A (6), 2,3-didehydrosomnifericin (7), withanone (8) and 6α-chloro-5β-
hydroxywithaferin A (9), withanolide A (10), withanoside IV (11) and withanoside X (12). 
Compound 3 was determined as a new structure and compound 4 was isolated from W. 
somnifera for the first time.[38] Several analogs of withaferin A were also prepared in this study 
for SAR and pre-clinical evaluations. All withanolides were initially screened for anti-
proliferative activity using the MTS assay. 
 
3.2 Botany and Collection of W. somnifera 
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W. somnifera raw plant material and extracts are currently sold as dietary supplements in the 
USA. To isolate large amounts of desired compounds, starting with plant extracts saved time, 
money, and effort on the plant extraction process. According to Jayaprakasam et al. (2003), this 
research group isolated considerable quantities of withaferin A and other withanolides from the 
plant extract of W. somnifera provided by PhytoMyco Research Corporation, Greenville, NC. 
We, therefore, purchased 200 g of plant extract from the same company in March 2009. 
According to the source, the extract was prepared by sequential extraction of the dried and 
ground leaves of W. somnifera with a mixture of CH2Cl2-MeOH (1:1) followed by MeOH and 
H2O to obtain three fractions. All fractions were then combined, filtered and dried under reduced 
pressure. The purchased original extract has been stored at -20 °C in our laboratory to serve as a 
reference material. Authentication documentation that accompanied the sample has been 
deposited in the natural product chemistry lab at The University of Kansas. 
 
3.3 Isolation of Withanolides from W. somnifera. 
 
The powdered, dried plant extract (189 g) of W. somnifera was dissolved in 2 L of water to form 
a suspension. The water layer was placed in a large separatory funnel to which 2 L of hexane 
were added in order to remove the non-polar lipophilic organics such as fatty acids. The hexane 
layer was subjected to two additional liquid-liquid partitions. The hexane layers were combined 
and concentrated under reduced pressure to obtain a total of 32.6 g of a crude hexane extract. 
The water layers were each further placed in the separatory funnel to which 2 L of EtOAc were 
added in order to extract organic compounds of mid-polarity. The extraction process was 
 
 
53 
repeated twice and the organic layers were combined and concentrated under reduced pressure to 
yield a total of 32.9 g of a crude EtOAc extract. Subsequently, the water layers were each 
extracted with BuOH three times (2 L × 3) to afford a total of 80.0 g of a crude BuOH extract, 
which contained most of the polar organics. After all the described extraction procedures were 
completed, the aqueous layers were discarded.  
 
The EtOAc extract was then subjected to passage over a Si gel column (600 g, 32~63 µm, 
Sorbent Technologies), eluted sequentially with acetone - CH2Cl2 solvent gradient (0-100%) 
followed by MeOH, to give eight major fractions (Fraction A-H; Table 3.1). Fraction F was 
further chromatographed on a Si gel (200 g, 12~26 µm, Sorbent Technologies) MPLC column, 
eluted with CH2Cl2-EtOAc-MeOH (40:10:1), to afford four additional fractions (F1-F4; Table 
3.2). Fraction F2 was applied onto a C-18 reverse phase column (100 g, Sorbent Technologies), 
eluted with MeOH-H2O (3:7) to remove the green color. The colorless fraction F2 was then 
separated on a Sephadex LH-20 column (200 g, GE Healthcare), eluted with MeOH to obtain the 
major components, and then purified by separation over a Si gel column (50 g, 12~26 µm, 
Sorbent Technologies), eluted with CH2Cl2-MeOH-EtOAc (18:1:1), to yield 3 (5 mg). HPLC 
chromatogram of 3 is shown in Figure 3.2. Fraction F1 was purified on a Sephadex LH-20 
column (200 g, GE Healthcare), eluted with MeOH, to afford 7 (21mg). Compound 8 (800mg) 
was obtained as fine needles by recrystallization of fraction D from CHCl3-acetone (1:1). 
Fraction E was chromatographed on a Si gel column, eluted with CH2Cl2-acetone (10:1), to 
collect twelve fractions (E1-El2, Table 3.3), and E6 was identified as 1 (34 mg). The major 
withanolide in fraction E7 was obtained as a white powder yielding 6 (22 mg) by recystallization 
from CHCl3-acetone (1:1). E12 was separated over a C-18 reverse phase SPE column (5 g, 20 ml, 
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Phenomenex strata C-18), eluted with MeOH-H2O (1:1), to give a mixture of two compounds 
(6.0 mg). Further purification of the mixture by HPLC using isocratic elution with acetonitrile-
water (45:55) provided 4 (1.5 mg) and 5 (1.2mg). Compound 9 (7.3 mg) was purified from 
fraction E11 by a C-18 reverse phase SPE column (5 g, 20 mL, Phenoment strata C-18) using 
MeOH-H2O (1:1). Compound 10 (521 mg) was purified as white powder by recrystallization of 
fraction C from CHCl3-MeOH (1:1). 
 
The BuOH extract was subjected to passage over a Si gel column (2 kg, 12~26 µm, Sorbent 
Technologies), eluted sequentially with MeOH-CH2Cl2 solvent gradient (30%- 100%), to give 21 
fractions (Table 3.4). Fraction 4-5 was purified on a Sephadex LH-20 column (200 g, GE 
Healthcare), eluted with MeOH-H2O (8:2), to afford a withanoside-rich fraction. This faction 
was further purified by PTLC eluting with CH2Cl2-MeOH-H2O (40:10:1) and semi-prep HPLC 
eluting with CH3CN-H2O (25:75) to afford two withanosides 11 (5.6 mg) and 12 (6.3 mg). 
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Figure 3.1. Withanolides and withanosides from Withania somnifera 
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Table 3.1.  Fractionation of EtOAc extract from W. somnifera.  
Fractions Wt. (in g) %Yielda 
A 4.2 12.8 
B 3.8 11.5 
C 6.7 20.4 
D 3.3 10.0 
E 6.0 18.2 
F 1.2 3.6 
G 1.4 4.2 
H 3.2 9.7 
aAs a percentage of the EtOAc extract (32.9 g) 
   
 
Table 3.2.  Fractionation of Fraction F from W. somnifera.  
Fractions Wt. (in g) %Yielda 
F1 0.25 6.9 
F2 0.31 8.6 
F3 1.22 33.9 
F4 1.12 31.1 
aAs a percentage of Fraction F (3.6 g) 
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Table 3.3.  Fractionation of Fraction E from W. somnifera. 
Fractions Wt. (in g) %Yielda 
E1 0.21 3.5 
E2 0.86 14.3 
E3 0.73 12.2 
E4 0.32 5.3 
E5 0.22 3.7 
E6 0.21 3.5 
E7 0.48 8.0 
E8 0.21 3.5 
E9 0.45 7.5 
E10 0.43 7.2 
E11 0.13 2.2 
E12 0.26 4.3 
aAs a percentage of Fraction E (6.0 g) 
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Table 3.4.  Fractionation of BuOH extract from W. somnifera. 
Fractions Wt. (in g) %Yielda 
1 6.3 7.8 
2 12.2 15.3 
3 0.49 0.6 
4 0.33 0.4 
5 0.58 0.7 
6 0.96 1.2 
7 0.85 1.1 
8 0.91 1.1 
9 0.97 1.2 
10 1.52 1.9 
11 1.64 2.1 
12 0.43 0.5 
13 0.55 0.7 
14 0.68 0.9 
15 0.79 1.0 
16 0.86 1.1 
17 3.54 4.4 
18 2.68 3.4 
19 5.63 7.0 
20 1.46 1.8 
21 1.83 2.3 
aAs a percentage of the BuOH extract  (80.0 g) 
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Figure 3.2. HPLC chromatogram of 6α-chloro-5β,17α-dihydroxywithaferin A (3). 
Mobile phase:  A-water, B-Acetonitrile; isocratic 50% B for 30 min 
Flow rate:  1 mL/minute 
Injection Vol.:  10 µm 
Injection Conc.: 1.0 mg/mL in Methanol 
Detection: 254 nm 
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 3.4 Structure Elucidation 
 
The 13C NMR data for compounds 3 - 12 are shown in Table 3.5, and data for proton NMR 
spectra have been presented in Figures 3.3 through 3.14. Fraction E6 was identified as 
withaferin A (compound 1 in Chapter II) by 1H NMR and co-chromatography with compound 1 
isolated from Vassobia breviflora. 
 
Compound 3 was obtained as colorless parallelepiped-shaped crystals by recrystallization from 
MeOH-CH2Cl2-EtOAc (5:1:1), having the molecular formula C28H39ClO7 as deduced from its 
HRESIMS (observed m/z 523.2440 [M + H]+, calcd for C28H40ClO7 523.2463) and NMR data. 
The presence of chlorine was supported by the intensity of the [M + H + 2]+ peak, which was 
approximately one-third as intense as the pseudomolecular ion peak [M + H]+ (Figure 3.4). IR 
absorption bands at 3500, 1700, and 1650 cm-1 revealed the presence of OH, carbonyl and 
lactonic groups.  
 
The 13C NMR (DEPT) spectrum of 3 displayed 28 signals assigned to four methyl, seven 
methylene (including one oxygenated at δ 57.3, nine methane (including two olefins at δ 127.8 
and δ 142.8), and eight quaternary carbons (including one keto carbonyl at δ 200.2 and one ester 
carbonyl at δ 167.0, two olefins at δ 154.2 and δ 125.2). The 13C NMR (DEPT) spectrum of 3 
displayed 28 signals assigned to four methyl, seven methylene (including one oxygenated at 
δ 57.3); nine methane (including two olefins at δ 127.8 and δ 142.8); and eight quaternary 
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carbons (including one keto carbonyl at δ 200.2 and one ester carbonyl at δ 167.0, two olefins at 
δ 154.2 and δ 125.2, two oxygenated at δ 84.8 and δ 78.1) and corresponding to C28H35.  Thus, 
the remaining four hydrogen atoms were assigned to four OH groups. These data were consistent 
with the characteristic features of withanolides, C28-steroidal lactones with a δ-lactone ring on 
the nine-carbon side chain.  
 
The 1H NMR spectrum of 3 (Figure 3.3A) also showed typical signals for a withanolide. After 
analyzing the COSY (Figure 3.3B), HSQC (Figure 3.3C), and HMBC (Figure 3.3D) spectra of 
3, the four methyl groups resonated at δ 0.99 (3H, d, J =7.0 Hz), δ 0.78 (3H, s), δ 1.27 (3H, s), 
and δ 2.03 (3H, s), corresponding to the secondary methyl of C-21 and the quaternary methyls at 
C-18, 19 and 28 of a withanolide. 
 
Finally, the structure of 3 was confirmed through single-crystal X-ray diffraction experiments. 
The absolute configuration of 3 was confirmed on the basis of anomalous scattering of the 
chlorine atoms in the crystal (Figure 3.5). Thus, the structure of the new withanolide 3 was 
established as 6α-chloro-5β,17α-dihydroxywithaferin A. [38] 
 
The known compounds were identified, by comparison of their NMR and MS data with those 
reported in the literature. The NMR data of compound 9 was very similar to those of compound 
3. The obvious difference between 3 and 9 was the presence of a quaternary carbon (δ 84.8) in 3 
and a methine carbon (C-17) in the latter (1H NMR δ  1.07, 13C NMR δ 51.8), suggesting that 9 
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(Figure 3.11) was a 17-dehydroxy derivative of 3. This observation was supported by the high-
frequency shift of C-13 (δ 48.3 in 3 and δ 43.2 in 9), C-16 (δ 36.5 in 3 and δ 27.2 in 9), and C-20 
(δ 42.6 in 3 and δ 38.7 in 9) in the 13C NMR spectra. It was also supported by the 1H-1H COSY 
and HSQC spectra (a fragment CH3-CH-CH(O)-CH2- of the side chain linked to the oxygenated 
quaternary C-17 in 3 and a fragment CH3-CH-CH(O)-CH2- of the side chain linked to methine 
C-17 in 9), and the HMBC correlations between H3-21 (δ 0.99) and C-17 (δ 84.8), and between 
H3-18 (δ 0.78) and C-17 (δ 84.8) in 3. Finally, the structure of 9 was confirmed as 6α-chloro-5β-
hydroxy withaferin A. The proton NMR of 7 (Figure 3.9) revealed that its structure is similar to 
9. The slight difference is that in 7, the function group attached to C-6 was a hydroxyl group (C-
6 in compound 7, δ 75.2) instead of chlorine (C-6 in compound 9, δ 66.7). Compound 7 was 
confirmed as 2,3-didehydrosomnifericin. 
 
Compound 5 was established as a 2,3-dihydroxy derivative of withaferin A (1), which was the 
same as compound 1a obtained by the hydrogenation of withaferin A (see Chapter II). Its NMR 
spectrum has been presented in Figure 3.7. Compared to 5, Compound 6 had an additional 3-
methoxy group, which showed a strong signal at δ 3.35 (3H, s) as can be seen in Figure 3.8. The 
C-3 (δ 26.5) in the 13C NMR spectrum of 5 shifted to δ 77.5, suggesting the oxygenated C-3 in 
compound 6. Compound 6 was further confirmed as 3-methoxy-2,3-dihydrowithaferin A. 
Compound 4 (22R)-5β-formyl-6β,27-dihydroxyl-1-oxo-4-norwith-24-enolide was different from 
all the other withanolides isolated in that the A ring of 4 was an unusual five member ring. The 
H-4 (δ 9.53) in proton NMR of 4 (Figure 3.6) indicated the presence of an aldehyde in the 
structure.  
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In the low-field region of the proton NMR of compound 8 (Figure 3.10), withanone, there were 
two signals for vinylic hydrogens at δ 5.83 and δ 6.58, which corresponded to an α,β - 
unsaturated A ring. Two mutually coupled adjacent protons at δ 3.03 and δ 3.30 supported a 6α-
7α-epoxy on the B ring. The proton NMR of compound 10 (Figure 3.12), which was later 
confirmed as withanolide A, was similar to that of compound 8. However, the chemical shift of 
C-20 at δ 75.3 (δ 42.9 in 8), C-17 at δ 54.6 (δ 84.6 in 8) and the singlet of H-21 at δ 1.30 in 
compound 10 suggested the presence of a hydroxyl group attached to C-20 instead of C-17 in 
compound 8. 
 
Detailed analysis of the 1D and 2D NMR spectra and comparison with the reported data 
established that compounds 11 and 12 were withanosides containing two glucose units. The 
aglycones corresponding to 11 and 12 were determined as pubesenolide [(20S,22R)-1α,3β,27-
trihydroxywitha-5,24-dienolide]. In compound 12, the sugar moieties were two glucose 
monosaccharide residues as established by β-anomeric proton signals (Figure 3.14) at δ 5.08 (d, 
J=8.0Hz, H-1’) and δ 5.09 (d, J=7.5Hz, H-1”). HMBC correlations of H-3 and C-1’, H-1’ and C-
3, H-27 and C-1”, as well as H-1” and C-27 suggested their linkage sites at C-3 and C-27 in 
compound 12. However, in compound 11 (Figure 3.13), the HMBC experiment showed long-
range correlations between H-1’ and C-3, and H-1” and C-6’. Based on this information and 
reported data, 11 and 12 were confirmed to be withanoside IV and withanoside X.  
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 Figure 3.3.  1D and 2D NMR spectra of 6α-chloro-5β,17α-dihydroxywithaferin A (3). 
A. 1H NMR spectrum (500 MHz, CDCl3) of 6α-chloro-5β,17α-dihydroxywithaferin A (3).  
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Figure 3.3.  1D and 2D NMR spectra of 6α-chloro-5β,17α-dihydroxywithaferin A (3) – (cont.) 
B. COSY spectrum of compound 3. 
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Figure 3.3.  1D and 2D NMR spectra of 6α-chloro-5β,17α-dihydroxywithaferin A (3) – (cont.) 
      C. HSQC spectrum of compound 3. 
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Figure 3.3.  1D and 2D NMR spectra of 6α-chloro-5β,17α-dihydroxywithaferin A (3) – (cont.) 
D. HMBC spectrum of compound 3. 
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  Figure 3.4. Mass spectrum of 6α-chloro-5β,17α-dihydroxywithaferin A (3). 
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 Figure 3.5. ORTEP view of 6α-chloro-5β,17α-dihydroxywithaferin A (3) from X-ray 
diffraction data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
70 
  Figure 3.6. 1H NMR spectrum (500 MHz, CDCl3) of (22R)-5β-formyl-6β,27-dihydroxy-1-oxo-
4-norwith-24-enolide (4). 
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Figure 3.7.  1H NMR spectrum (500 MHz, CDCl3) of 2,3-dihydrowithaferin A (5).  
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Figure 3.8. 1H NMR spectrum (500 MHz, CDCl3) of 3-methoxy-2,3-dihydrowithaferin A (6).  
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Figure 3.9. 1H NMR spectrum (500 MHz, CD3OD) of 2,3-didehydrosomnifericin (7).  
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 Figure 3.10.  1H NMR spectrum (500 MHz, CDCl3) of withanone (8).  
O
OOH
O
OOH
H
H
H
HH
 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
f1 (ppm)
2
.9
2
2
.9
6
2
.9
2
2
.0
7
4
.4
5
3
. 0
8
7
. 0
6
2
.1
7
1
.0
1
3
.0
6
1
.0
0
1
.0
0
0
.9
8
0
.9
8
1
.0
1
0
.9
9
0
.9
8
1
.0
0
0
.8
3
1
.0
0
1
. 1
2
1
.2
8
1
.3
2
1
.5
1
1
. 5
9
1
.6
8
1
.7
3
1
.8
5
2
.0
1
2
.1
5
2
.2
7
2
.4
1
2
.5
0
2
.6
4
2
.7
8
2
.8
0
3
.0
3
3
. 0
3
3
.1
4
3
. 2
9
3
.3
0
3
.3
0
3
.3
0
4
.5
7
4
. 5
8
4
. 5
8
4
.5
8
4
.5
9
4
. 6
0
4
.6
0
4
.6
1
5
. 8
2
5
.8
2
5
.8
3
5
.8
4
5
.8
4
6
.5
6
6
.5
6
6
.5
7
6
. 5
7
6
.5
8
6
.5
8
6
.5
9
6
. 5
9
H-3
H-22
H-28
H-27
H-19
H-21
H-18
H-2
H-7
H-6
 
 
 
75 
Figure 3.11. 1H NMR spectrum (500 MHz, CDCl3) of 6α-chloro-5β-hydroxywithaferin A (9).  
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Figure 3.12. 1H NMR spectrum (500 MHz, CDCl3) of withanolide A (10).  
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Figure 3.13. 1H NMR spectrum (500 MHz, pyridine-d5) of withanoside IV (11).  
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Figure 3.14. 1H NMR spectrum (500 MHz, pyridine-d5) of withanoside X (12). 
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Table. 3.5. 13C NMR data for compounds 3-12. 
 3a 4a 5a 6a 7b 8a 9a 10a 11c 12c 
C1 200.2 216.3 210.3 209.9 204.0 203.7 200.1 203.4 72.8 72.8 
C2 127.8  32.0 39.6 127.9 129.0 127.8 129.2 38.4 38.4 
C3 142.8  26.9 77.5 147.7 139.7 142.8 139.9 74.8 74.3 
C4 66.1 204.2 72.2 75.1 68.2 36.7 66.2 36.9 39.6 39.6 
C5 78.1 60.4 65.8 65.0 80.3 73.7 78.1 73.5 139.8 139.7 
C6 66.5 67.4 58.3 60.4 75.2 56.3 66.7 56.5 124.4 124.4 
C7 39.3  29.2 31.2 38.2 57.0 39.4 57.5 32.7 32.8 
C8 35.2  31.0 29.4 35.1 36.0 35.1 35.7 32.5 32.7 
C9 45.3 41.8 42.5 42.8 46.2 35.2 45.8 35.2 41.8 42.0 
C10 57.1 52.3 50.0 50.4 57.4 50.9 57.2 51.2 42.4 42.6 
C11 22.4  21.1 21.6 24.0 21.6 22.7 23.4 21.0 20.9 
C12 31.6  27.3 39.1 40.5 32.7 39.0 40.6 40.1 40.1 
C13 48.3  42.3 42.7 44.1 48.7 43.2 44.1 43.2 43.3 
C14 49.6  55.9 56.0 56.6 45.9 55.3 52.1 56.8 56.9 
C15 23.3  23.8 24.3 25.2 22.9 24.0 22.0 27.7 27.7 
C16 36.5 27..0 38.7 27.3 28.2 36.6 27.2 21.9 25.0 25.0 
C17 84.8 51.6 51.4 51.9 53.0 84.6 51.8 54.6 52.5 52.5 
C18 14.8 12.0 11.3 11.6 10.5 15.1 11.8 14.0 12.2 12.1 
C19 9.9 13.2 15.0 15.7 12.2 14.7 9.9 15.0 20.1 19.9 
C20 42.6 38.7 38.1 38.8 40.3 42.9 38.7 75.3 39.5 39.5 
C21 9.4 13.4 13.3 13.4 13.6 9.5 13.3 21.3 14.0 13.9 
C22 78.9 78.8 78.2 78.8 80.1 78.7 78.6 81.2 78.9 78.7 
C23 32.9 29.1 28.9 29.8 30.7 32.4 29.8 31.9 30.4 29.9 
C24 154.2 152.7 152.0 153.0 157.8 150.5 152.7 149.1 154.3 157.4 
C25 125.2 126.0 125.2 125.7 120.4 121.4 125.7 122.2 127.8 124.5 
C26 167.0 167.0 167.0 167.1 168.5 167.2 166.9 166.3 166.8 166.4 
C27 57.3 57.5 57.5 57.5 56.3 12.4 57.4 12.7 56.7 63.9 
C28 20.0 20.0 20.0 20.1 20.2 20.5 20.0 20.8 21.0 20.5 
Glc-1’        103.7 103.3 
2’        75.6 75.8 
3’        78.8 79.1 
4’        71.8 71.9 
5’        77.4 78.8 
6’        70.2 63.0 
Glc-1”        106.0 105.4 
2”        75.5 75.7 
3”        78.9 79.1 
4”        72.0 72.1 
5”        78.7 79.0 
6”  
C3-O-CH3 
    
56.86 
  63.1 63.2 
 
a In CDCl3, δ (ppm) 125Hz; 
b In CD3OD, δ (ppm) 125Hz; 
c In pyridine-d5, δ (ppm) 125Hz; 
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3.5 Experimental 
 
Optical rotations were obtained on a Rudolph Research Analytical Autopol IV Automatic 
polarimeter. Melting points were recorded using a MPA100 OptiMelt Automated Melting Point 
System (Stanford Research Systems, Sunnyvale, CA). UV data were acquired using an Agilent 
Technologies 1200 HPLC (Diode Array Detector). HPLC was conducted on Agilent 
Technologies 1200 series system. IR data were obtained using a Thermo Nicolet Avatar 360 FT-
IR instrument. NMR spectra were recorded on either a Bruker DRX-400 with a qnp probe or on 
a Bruder AV-500 with a cryoprobe. 1H and 13C spectra were recorded using the residual 
protonated signal in the CDCl3 solvent (δH 7.24) or the central peak of the CDCl3 triplet (δC 
77.00) as the internal standard. High resolution mass spectrometry data were collected on a LCT 
Premier time of flight mass spectrometer (Waters Corp., Milford, MA). Normal phase TLC was 
performed on Sorbent Technologies Silica G TLC plates (200 µm, w/UV 254) using the solvent 
system DCM-EtOAc-MeOH (1:8:1), and reverse phase TLC was performed on Sorbent 
Technologies C18 TLC plates (150 µm, w/UV 254) using H2O-MeOH (1:1). Spots were 
visualized using UV light (254 nm) and spraying with vanillin-sulfuric acid reagent. 
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IV. LARGE-SCALE ISOLATION OF WITHAFERIN A FROM ROOTS OF WITHANIA 
SOMNIFERA 
 
4.1 Introduction 
 
Our interest in anti-proliferative activity of natural products and namely of withaferin A, led us 
to determine the chemistry and mechanisms responsible for its activity (see Chapter II). As 
follow–up studies will be necessary to further evaluate the potential of application of withaferin 
A for future translational studies in head and neck squamous carcinoma, we developed a large-
scale isolation method for withaferin A for the future clinical studies.  
 
We did not get sufficient quantities of withaferin A for the planned pre-clinical studies from an 
organic plant extract of W. somnifera purchased from PhytoMyco Research Corporation 
(discussed in chapter III). We considered, therefore, the purchase of roots of W. somnifera as our 
new source for the isolation of gram quantities of withaferin A. Roots and leaves of W. somnifera 
are traditionally used plant parts with different medicinal properties and uses in the Ayurvedic 
system of medicine. The powdered root of W. somnifera is also used as a nutrient and for health 
restoration to give energy and vigor. Reported HPLC analysis shows that roots have, in general, 
larger quantities of withanolides as compared to stems.[39] 
 
4.2 Plant Material 
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The root powder (130 kg) of W. somnifera was purchased from Kalyx.com, Tamaqua, 
Pennsylvania in November 2009.  The new plant material was accompanied by a certificate of 
analysis which has been deposited in the natural product chemistry lab at The University of 
Kansas for future reference.  
 
4.3 Isolation of Withaferin A 
 
Several batches of powdered roots of W. somnifera (30 Kg) were each extracted at room 
temperature for one week using 60 L of MeOH. After filtration, the plant filtrate was 
concentrated under reduced pressure using a rotary evaporator to get 600 g of a brown and sticky 
residue. This process was repeated one additional time using the same conditions to produce an 
additional 400 g of plant extract.  
 
The total plant extract (1 kg) was divided into ten portions and each portion (100 g) was 
dissolved in 1.5 L of water to form a suspension. The water layer was placed in a large 
separatory funnel to which 1.5 L of hexane were added in order to remove the non-polar 
lipophilic organics such as fatty acids. The hexane layer was subjected to two additional liquid-
liquid partitions. The hexane layers were combined and concentrated under reduced pressure to 
obtain a total of 110 g of a crude hexane extract. The water layers were each further placed in the 
separatory funnel to which 1.5 L of EtOAc were added in order to extract organic compounds of 
mid-polarity. The extraction process was repeated twice and the organic layers were combined 
and concentrated under reduced pressure to yield a total of 120 g of a crude EtOAc extract. 
Subsequently, the water layers were each extracted with BuOH three times (1 L × 3) to afford a 
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total of 220 g of a crude BuOH extract, which contained most of the polar organics. After all the 
described extraction procedures were completed, the aqueous layers were discarded.  
 
Thin layer chromatography (TLC) of the hexane, EtOAc and BuOH extracts were co-
chromatographed along with pure withaferin A as a standard reference compound. The TLC 
profiles showed that most of withaferin A was present in the EtOAc extract. As the isolation of 
pure withaferin A was the main focus of this project, we concentrated our efforts on its isolation 
from the EtOAc extract. TLCs were performed on Sorbent Technologies Silica Gel TLC plates 
(200 µm, w/UV 254) using the solvent system acetone-CH2Cl2 (1:4) and vanillin-sulfuric acid 
reagent as a visualization agent. Based on the TLC results, we decided to perform large scale 
(120 g of crude sample) column chromatography using silica gel (12~26 µm) and acetone- 
CH2Cl2 (1:9) as eluent.  
 
The EtOAc extract (120 g) was dissolved with 1 L of EtOAc and added to 160 g of silica gel 
(12~26 µm). The mixture was dried under reduced pressure to afford yellow fine free-flowing 
powder. This EtOAc extract-silica gel mixture was subjected to passage over a silica gel column 
(column size: 150 mm × 600 mm; silica gel: 2 kg, 12~26 µm, Sorbent Technologies), which was 
then eluted sequentially with acetone- CH2Cl2 (1:9) to yield 31 fractions (Fractions 1-31; Table 
4.1). TLC of each fraction was conducted during this process in order to monitor for the presence 
of withaferin A. Fractions 15-19 were shown to contain withaferin A and these were combined 
and dried under reduced pressure to afford 6.1 g of a yellow sticky residue.  
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The withaferin A-containing sample was placed in a pear shape flask and was dissolved in 20 ml 
of CHCl3 and an equivalent amount of MeOH was added drop by drop. A piece of aluminum foil 
was placed over the flask and 5-8 small holes were punched to allow for a slow evaporation of 
the solvent at room temperature. After two weeks, light yellow and transparent crystals of 
withaferin A (4.5 g, 90% purity) were formed. In order to obtain a purer withaferin A, a second 
crystallization process was performed using the exact same method. After two weeks, colorless 
transparent crystals of withaferin A (4.0 g, 95% purity) were obtained. 
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Table 4.1. Fractions 1-31: Weights and Yields profile. 
Fractions Wt. (in g) %Yielda 
1 0.4 0.3 
2 0.7 0.6 
3 1.9 1.6 
4 6.2 5.2 
5 5.7 4.8 
6 4.7 3.9 
7 3.9 3.3 
8 6.1 5.1 
9 4.1 3.4 
10 2.8 2.3 
11 2.7 2.3 
12 2.9 2.4 
13 2.1 1.8 
14 1.0 0.8 
15 0.3 0.3 
16 2.2 1.8 
17 1.6 1.3 
18 1.2 1.0 
19 0.8 0.7 
20 2.2 1.8 
21 2.3 1.9 
22 2.6 2.2 
23 1.7 1.4 
24 2.3 1.9 
25 2.3 1.9 
26 1.9 1.6 
27 3.2 2.7 
28 2.4 2.0 
29 1.3 1.1 
30 0.9 0.8 
31 1.2 1.0 
aAs a percentage of the EtOAc extract  (120.0 g)
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4.4 Identification of Withaferin A 
 
After recrystallization, the colorless transparent crystals (4.0 g) were identified as withaferin A 
(compound 1 in Chapter II) by 1H NMR and co-chromatograph with compound 1 isolated from 
Vassobia breviflora.  
 
4.5 Experimental 
 
NMR spectra were recorded on a Bruker DRX-400 with a qnp probe. 1H and 13C spectra were 
recorded using the residual protonated signal in the CDCl3 solvent (δH 7.24) or the central peak 
of the CDCl3 triplet (δC 77.00) as the internal standard. Normal phase TLC was performed on 
Sorbent Technologies Silica G TLC plates (200 µm, w/UV 254) using the solvent systems 
CH2Cl2-EtOAc-MeOH (1:8:1) and acetone- CH2Cl2 (1:4). Spots were visualized using UV light 
(254 nm) and by spraying with vanillin-sulfuric acid reagent. 
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V. SUMMARY AND CONCLUSIONS 
 
The research described here illustrated the isolation, characterization and biological activities of 
withanolides from the Argentinean plant Vassobia breviflora and the Indian plant Withania 
somnifera. The primary goal of this research was for anti-cancer drug lead discovery from 
medicinal plants. Following an introductory chapter describing the background and motivation 
for research into natural products, chapter 2 demonstrated how bioassay guided fractionation can 
lead to the identification of anti-proliferative agents. A total of 200 Latin American plants were 
evaluated for their cytotoxic activities. From one of the most active plants, Vassobia breviflora, 
the anti-proliferative active compound withaferin A (1) was isolated, along with another 
withanolide, viscosalactone B (2). The later biological study provided a possible anti-
proliferative mechanism for withaferin A. In addition, three analogues, 2,3-Dihydrowithaferin A 
(1a), 2,3-dihydro-27-deoxywithaferin A (1b) and diacetylwithaferin A (1c), were semi-
synthesized from withaferin A for the anti-proliferative SAR studies.   
 
Chapter 3 used a series of chromatographic separations and spectroscopic experiments to 
separate and identify 10 additional withanolides, 6α-chloro-5β,17α-dihydroxywithaferin A (3), 
(22R)-5β-formyl-6β,27-dihydroxy-1-oxo-4-norwith-24-enolide (4), 2,3-dihydrowithaferin A (5), 
3-methoxy-2,3-dihydrowithaferin A (6), 2,3-didehydrosomnifericin (7), withanone (8) and 6α-
chloro-5β-hydroxywithaferin A (9), withanolide A (10), withanoside IV (11) and withanoside X 
(12), from Withania somnifera. During this study, a new compound 6α-chloro-5β,17α-
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dihydroxywithaferin A was isolated and (22R)-5β-formyl-6β,27-dihydroxy-1-oxo-4-norwith-24-
enolide was found in W. somnifera for the first time. A method for large-scale isolation of 
withaferin A was presented in chapter 4. This method was developed to isolate four grams of 
pure withaferin A from 30 kilograms of W. somnifera. 
 
This thesis described many natural products chemistry techniques including 1D and 2D NMR, 
mass spectroscopy, and a number of chromatography experiments. The compound 3 from W. 
somnifera was a novel withanolide with an unusual chlorine substitution on the B ring. The 
structure of this compound was first elucidated based on NMR, then confirmed by single crystal 
X-ray crystallography.  
 
The biological studies demonstrated that withaferin A had anti-proliferative and apoptotic 
inducing properties on HNSCC cells. The growth inhibitory effect of withaferin A in HNSCC 
cells was accompanied by a G2/M arrest in cell cycle. All withanolides in this study were 
evaluated in assays for anti-proliferative activities against HNSCC cells. Results obtained in 
these studies suggested the importance of some structure features of withaferin A for it observed 
anti-proliferative activity. The α,β-unsaturated A ring and 5,6-epoxy-4-ol are important for its 
anti-proliferative activity.  
 
Recent studies beyond the scope of this thesis were performed by our collaborators, Dr. Mark 
Cohen, at KU medical center. In vitro tests indicated that withaferin A was an Hsp90 modulator, 
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with inhibition of HSF-1, Akt and caspase-3 expression and cleavage of PARP.[40] In vivo 
animal studies by also demonstrated that withaferin A was a RET (rearranged during transfection) 
inhibitor and had significant efficacy against medullary thyroid cancer.[41] Recent published 
withaferin A anticancer mechanism studies reported that withaferin A induces endoplasmic 
reticulum (ER) stress[42] and inhibition of the NF-κB signaling pathway.[43] Based on the 
reported biological studies, withaferin A and its analogues are the potential drug leads for the 
treatment of cancer[30], neurodegenerative[33], inflammatory[35], and cardiovascular[32] 
diseases. 
 
The work presented here demonstrated a natural product approach to discovering potential 
botanical new drug leads, which starts with a library of plant extracts to one plant, then to one 
active compound, and to a series of analogues at the end. The work also showed how to optimize 
the small-scale isolation method and apply it to a large-scale isolation for sufficient materials for 
pre-clinical studies. This work was published in two papers[22][38] and also contributed to a 
patent application.[44] This thesis emphasized the importance of natural products to the 
discovery of biological active agents, and concluded that natural products have long been and 
will continue to be important to the anti-cancer drug research. The future direction of this 
research will concern on the total synthesis of withanolide-type compounds, the searching of 
novel withanolides from other plant species, the elaborate anti-proliferative SAR studies and the 
further anti-proliferative clinical studies of withaferin A and its analogues.  
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